Professor of Biomedical Data Science (Assistant, Associate, and/or Professor level)

Department Overview

The OHSU Knight Cancer Institute (KCI) Known as one of the pioneers in personalized cancer medicine, KCI at OHSU is an international leader in research and practice of cancer prevention, detection, and treatment, driven by its mission to end cancer as we know it. KCI envisions a world freed from the burden of cancer by working in a collaborative and team-based environment to make bold advances in understanding cancer biology, detection, treatment, and survival. The KCI is an NCI-designated Cancer Center. It is also the headquarters for the NCI’s SWOG collaborative, a cancer research cooperative group that designs and conducts multidisciplinary clinical trials to improve the practice of medicine for preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors. KCI is home to world-renowned leaders in oncology: Brian J. Druker, MD, Director of the OHSU Knight Cancer Institute and JELD-WEN Chair of Leukemia Research, made one of the most celebrated cancer discoveries in a generation—the targeted drug Gleevec; Gordon Mills, MD, PhD, one of the most cited medical scientists, joined the Knight in 2018 to lead precision oncology; and Sadik Esener, PhD, the founding director of the Cancer Early Detection Advanced Research Center (CEDAR) which is pioneering novel ways to eliminate cancers at the earliest stages.

 

Public support and private philanthropy, including a record-setting $1 billion fundraising campaign, with $500 million donated by Phil Knight and his wife, Penny, have provided crucial resources to advance its progress. In 2018, KCI completed the Knight Cancer Research Building, a 320,000-square-foot building with a unique design that will bring together people from different scientific disciplines with the goal of accelerating research progress. With a capacity of 650 occupants, the building houses the majority of researchers contributing to the Knight Cancer Institute’s mission including the Cancer Early Detection Advanced Research (CEDAR) Center.

 

Division of Oncological Sciences (DOS) The primary mission of DOS is discovery-based oncology research. DOS research also spans the translational landscape to reduce the burden of disease across the cancer continuum. DOS forms a critical nexus for cancer researchers, the OHSU clinical enterprise and the broader population we serve. As the research and educational branch of KCI, DOS is highly integrated with innovative patient-oriented KCI focus areas and population science approaches. Through a better understanding of how cancer initiates, progresses and invades, new strategies will be developed to prevent, detect and treat this disease. A foremost priority is to experimentally decipher transitions from normal to cancer, cancer to metastasis and metastasis to resistance. Translation of our findings will be facilitated through our high risk clinics, unique clinical trials, a Technology Accelerator and a robust program in medicinal chemistry and preclinical development to find new therapies to help our patients and enable new start-up ventures. Additional efforts aim to better understand the unique factors that contribute to cancer prevention and control within populations, particularly those at risk for cancer health disparities. Translation of these findings to develop, deploy and implement interventions in clinical and community practice can advance healthcare systems, policies and public health. 

 

DOS is comprised of non-clinical faculty, trainees and staff dedicated to basic, translational and population-based research that supports the strategic vision of the Knight Cancer Institute.  The division is organized around four areas: (1) Precision Systems Oncology. It includes Precision Early Detection through the Cancer Early Detection Advanced Research (CEDAR) Center (CEDAR) and Precision Oncology through the SMMART program (SMMART). Both programs rely on the integration of emerging capabilities in imaging and OMICS technologies, innovative model systems, cohort building and unique clinical trials to generate novel insights, development and translation of discoveries to practice; (2) Cancer Data Science (includes Computational Biology, Bioinformatics and Biostatistics); (3) Chemical Biology and Experimental Therapeutics, for translating basic research into drug discovery and development projects, and (4) Cancer Population Science, which studies cancer etiology, identifies environmental, behavioral, social and genetic factors associated with  cancer risk and outcomes in individuals and communities.

Function/Duties of Position

The Center for Biomedical Data Science (CBDS) at the Knight Cancer Institute (KCI) at Oregon Health and Science University (OHSU) is searching for multiple tenured or tenure-track faculty positions at all ranks (Assistant Professor, Associate Profess